Tasly Pharma Gains NMPA Green Light for CAR-T Therapy Clinical Study in Recurrent Glioblastoma
China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received approval from...
Cell-therapy
Juventas Cell Therapy Secures China Clinical Trial Approval for Inaticabtagene Autoleucel in AIHA
Chinese firm Juventas Cell Therapy Ltd has obtained tacit clinical trial approval in China for...
HemaCell’s XJ-MK-002 Gains FDA Orphan Drug Designation for Giant Platelet Syndrome
China-based Suzhou Xueji Biotechnology Co., Ltd (HemaCell), a pioneer in platelet regeneration-focused cell therapy, announced...
Guojian Qingke Biomedical Gains NMPA Approval for 3D MSCs in Stroke Trials
China-based Guojian Qingke Biomedical Technology (Beijing) Co., Ltd. announced that it has received tacit clinical...
Guangzhou Doublle Bioproduct Receives IND Approval for E101 in Type 2 Diabetes
Guangzhou Doublle Bioproduct Co., Ltd. has announced receiving Investigational New Drug (IND) clearance from China’s...
Suzhou Xueji Biotech’s XJ-MK-002 Gets FDA Orphan Drug Designation for CAMT
China-based cell therapy developer Suzhou Xueji Biotechnology Co., Ltd’s (HemaCell) XJ-MK-002, described as the world’s...
BMS’s Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma
US giant Bristol-Myers Squibb (BMS; NYSE: BMY) announced receiving another indication approval from the European...
Tasly Pharma’s NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial
China-based Tasly Pharma Co., Ltd (SHA: 600535) announced receiving approval from the National Medical Products...
Jiuzhitang’s Stem Cell Therapy for Autism Receives NMPA Clinical Trial Approval
China-based Jiuzhitang Co. Ltd (SHE: 000989) announced receiving clinical trial approval from the National Medical...
Astellas Pharma and YASKAWA Establish JV for Cell Therapy Product Manufacturing Platform
Japan-based Astellas Pharma Inc. (TYO: 4503) is set to establish a joint venture (JV) with...
Bayer’s BlueRock Therapeutics Gets Fast Track for OpCT-001 Therapy
German pharmaceutical giant Bayer (ETR: BAYN) and its wholly owned subsidiary BlueRock Therapeutics LP announced...
CARsgen Therapeutics Administers KJ-C2219 in SLE Patient in IIT
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that it has administered its KJ-C2219 at...
Cell Store and Cygenta Forge Strategic Alliance in Cell and Gene Therapy Field
Beijing-based biotech firms Cell Store, a biological sample cryopreservation technology platform, and Cygenta, a Contract...
Nuwacell Biotech’s NCR101 Approved for ILD Clinical Study by China’s CDE
According to the Center for Drug Evaluation (CDE) website, China-based Nuwacell Biotechnology Co., Ltd. has...
IASO Bio’s Fucaso NDA Accepted by Hong Kong DOH for Relapsed/Refractory Multiple Myeloma
China-based IASO Bio announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen...
Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study
Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the...
VectorBuilder and Eureka Bio Form Alliance to Advance CGT Solutions Globally
China-based gene delivery technology developer VectorBuilder has formed a strategic alliance with compatriot firm Shenzhen...
IASO Bio’s CAR-T Therapy Fucaso Accepted for Review in Singapore
China-based IASO Biotherapeutics has announced that a New Drug Application (NDA) for its BCMA-targeted chimeric...
Shenzhen Beike Initiates First Chinese Stem Cell Study for Systemic Lupus Erythematosus
China-based stem cell specialist Shenzhen Beike Biotechnology Co., Ltd has announced the initiation of a...
Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies
Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its...